You are here
Treatment Associated Side Effects
The Risk of Tuberculosis in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor-α Antagonist: A Metaanalysis of Both Randomized Controlled Trials and Registry/Cohort Studies
Jing-Wen Ai, Shu Zhang, Qiao-Ling Ruan, Yi-Qi Yu, Bing-Yan Zhang, Qi-Hui Liu, and Wen-Hong ZhangJ Rheumatol December 2015 42(12):2229-2237
Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force
Strehl C, Bijlsma JW, de Wit M, Boers M, Caeyers N, Cutolo M, Dasgupta B, Dixon WG, Geenen R, Huizinga TW, Kent A, de Thurah AL, Listing J, Mariette X, Ray DW, Scherer HU, Seror R, Spies CM, Tarp S, Wiek D, Winthrop KL, Buttgereit FAnn Rheum Dis. 2016 Jun;75(6):952-7.
Glucocorticoid-induced osteoporosis: pathophysiological role of GH/IGF-I and PTH/VITAMIN D axes, treatment options and guidelines
Mazziotti G, Formenti AM, Adler RA, Bilezikian JP, Grossman A, Sbardella E, Minisola S, Giustina A.Endocrine. 2016 Dec;54(3):603-611. Epub 2016 Oct 20.
Hoes JN1, Bultink IE, Lems WF.Expert Opin Pharmacother. 2015 Mar;16(4):559-71
Highlights the impact of treat-to-target to limit osteopenia, and the need to proactively diagnose and manage osteoporosis in patients with active rheumatoid arthritis
Interview with Prof. Willem Lems at EULAR 2016Q. Thanks very much, Will, for joining us this morning to talk about treating difficult osteoporosis in patients with high...
Interview with Prof. Bernard CombeThere is a wide debate in the medical community regarding the balance between efficacy and safety of glucocorticoid use. Prof...